Veradigm (MDRX) 10-Q 9 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 30, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'MDRX	'
Entity Registrant Name	'ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.	'
Entity Central Index Key	'0001124804	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	179,483,355

CONSOLIDATED_BALANCE_SHEETS_Un

CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$41,580	$62,954
Accounts receivable, net of allowance of $51,285 and $54,252 at March 31, 2014 and December 31, 2013, respectively	341,591	313,486
Deferred taxes, net	55,466	55,468
Prepaid expenses and other current assets	103,218	107,911
Total current assets	541,855	539,819
Long-term marketable securities	1,313	1,329
Fixed assets, net	168,026	174,013
Software development costs, net	85,177	88,244
Intangible assets, net	442,053	455,971
Goodwill	1,190,603	1,189,585
Deferred taxes, net	7,361	7,361
Other assets	197,850	163,341
Total assets	2,634,238	2,619,663
Current liabilities:	'	'
Accounts payable	68,962	72,956
Accrued expenses	82,245	96,499
Accrued compensation and benefits	53,156	80,196
Deferred revenue	305,602	251,038
Current maturities of long-term debt and capital lease obligations	19,139	16,350
Total current liabilities	529,104	517,039
Long-term debt	529,755	545,133
Deferred revenue	28,769	29,080
Deferred taxes, net	83,228	79,694
Other liabilities	155,762	130,572
Total liabilities	1,326,618	1,301,518
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Preferred stock: $0.01 par value, 1,000 shares authorized, no shares issued and outstanding at March 31, 2014 and December 31, 2013	0	0
Common stock: $0.01 par value, 349,000 shares authorized at March 31, 2014 and December 31, 2013; 264,093 and 179,421 shares issued and outstanding at March 31, 2014, respectively; 263,474 and 178,802 shares issued and outstanding at December 31, 2013, respectively	2,641	2,635
Treasury stock: at cost, 84,672 at March 31, 2014 and December 31, 2013	-278,036	-278,036
Additional paid-in capital	1,727,017	1,716,847
Accumulated deficit	-142,298	-121,556
Accumulated other comprehensive loss	-1,704	-1,745
Total stockholders' equity	1,307,620	1,318,145
Total liabilities and stockholders' equity	$2,634,238	$2,619,663

CONSOLIDATED_BALANCE_SHEETS_Un1

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, except Per Share data, unless otherwise specified
Statement Of Financial Position [Abstract]	'	'
Accounts receivable, allowance	$51,285	$54,252
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	1,000	1,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	349,000	349,000
Common stock, shares issued	264,093	263,474
Common stock, shares outstanding	179,421	178,802
Treasury stock at cost, shares	84,672	84,672

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Revenue:	'	'
System sales	$23,389	$27,031
Professional services	50,364	61,084
Maintenance	117,077	117,708
Transaction processing and other	149,455	141,243
Total revenue	340,285	347,066
Cost of revenue:	'	'
System sales (excluding amortization of software development costs and acquisition-related assets shown below)	7,983	13,329
Professional services	47,900	57,582
Maintenance	35,720	36,597
Transaction processing and other	89,465	85,591
Total cost of revenue	202,099	212,638
Gross profit	138,186	134,428
Selling, general and administrative expenses	89,946	104,232
Research and development	52,305	50,659
Asset impairment charges	195	319
Loss from operations	-11,911	-28,283
Interest expense	-7,233	-4,637
Other (expense) income, net	-32	8,131
Loss before income taxes	-19,176	-24,789
Income tax (provision) benefit	-1,566	13,197
Net loss	-20,742	-11,592
Loss per share-basic and diluted	($0.12)	($0.07)
Direct Cost Of Revenues [Member]	'	'
Cost of revenue:	'	'
Amortization of software development and acquisition-related assets	21,031	19,539
Other Costs [Member]	'	'
Cost of revenue:	'	'
Amortization of intangible and acquisition-related assets	$7,651	$7,501

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Statement Of Income And Comprehensive Income [Abstract]	'	'
Net loss	($20,742)	($11,592)
Other comprehensive income (loss), net of taxes:	'	'
Unrealized gain (loss) on marketable securities, net of tax	2	4
Derivatives qualifying as hedges:	'	'
Unrealized loss on interest rate swap	-33	-6
Reclassification adjustment for loss included in net loss	199	359
Tax effect	-66	-136
Unrealized gain on interest rate swap, net of tax	100	217
Change in foreign currency translation adjustments	-61	-739
Total other comprehensive income (loss)	41	-518
Comprehensive loss	($20,701)	($12,110)

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:	'	'
Net loss	($20,742)	($11,592)
Adjustments to reconcile net loss to net cash provided by operating activities:	'	'
Depreciation and amortization	45,127	41,997
Stock-based compensation expense	10,070	8,004
Excess tax benefits from stock-based compensation	-1,132	-1,654
Deferred taxes	4,398	-14,080
Asset impairment charges	195	319
Change in fair value of 1.25% call option and cash conversion option	56	0
Other losses (gains), net	1,407	-8,575
Changes in operating assets and liabilities, net of business combinations:	'	'
Accounts receivable, net	-28,178	-10,905
Prepaid expenses and other assets	2,363	-12,832
Accounts payable	-889	21,735
Accrued expenses	-14,255	-7,616
Accrued compensation and benefits	-27,027	849
Deferred revenue	54,248	35,462
Other liabilities	-4,353	-1,746
Net cash provided by operating activities	21,288	39,366
Cash flows from investing activities:	'	'
Capital expenditures	-11,945	-16,435
Capitalized software	-9,144	-7,871
Cash paid for business acquisitions, net of cash acquired	0	-148,802
Purchases of marketable securities, other investments and related intangible assets	-5,968	0
Sales and maturities of other investments	19	12,516
Proceeds from sale of fixed assets	55	0
Net cash used in investing activities	-26,983	-160,592
Cash flows from financing activities:	'	'
Proceeds from issuance of common stock	1,673	7,931
Excess tax benefits from stock-based compensation	1,132	1,654
Taxes paid related to net share settlement of equity awards	-3,184	-1,648
Payments of capital lease obligations	-110	-182
Credit facility payments	-30,313	-27,614
Credit facility borrowings, net of issuance costs	15,000	129,043
Net cash (used in) provided by financing activities	-15,802	109,184
Effect of exchange rate changes on cash and cash equivalents	123	314
Net decrease in cash and cash equivalents	-21,374	-11,728
Cash and cash equivalents, beginning of period	62,954	103,956
Cash and cash equivalents, end of period	$41,580	$92,228

CONSOLIDATED_STATEMENTS_OF_CAS1

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Parenthetical) (Senior cash convertible notes [Member])	Mar. 31, 2014	Mar. 31, 2013
Senior cash convertible notes [Member]	'	'
Change in fair value	1.25%	1.25%

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	1. Summary of Significant Accounting Policies
	Principles of Consolidation
	The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” or “our” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries, unless otherwise stated.
	Unaudited Interim Financial Information
	The unaudited interim consolidated financial statements as of and for the three months ended March 31, 2014 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the consolidated financial statements for the periods presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The results of operations for the three months ended March 31, 2014 are not necessarily indicative of the results to be expected for the year ending December 31, 2014.
	Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been omitted in accordance with the SEC’s rules and regulations for interim reporting. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2013 (our “Form 10-K”).
	Use of Estimates
	The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Actual results could differ materially from these estimates.
	Significant Accounting Policies
	There have been no changes to our significant accounting policies from those disclosed in our Form 10-K.
	Recently Adopted Accounting Pronouncements
	In March 2013, the FASB issued updated authoritative guidance to resolve the diversity in practice about whether FASB Account Standards Codification (“ASC”) Subtopic 810-10, Consolidation—Overall, or ASC Subtopic 830-30, Foreign Currency Matters—Translation of Financial Statements, applies to the release of the cumulative translation adjustment into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business (other than a sale of in substance real estate or conveyance of oil and gas mineral rights) within a foreign entity. In addition, this guidance resolves the diversity in practice for the treatment of business combinations achieved in stages (sometimes also referred to as step acquisitions) involving a foreign entity. This guidance is effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2013 and we adopted the new guidance in the first quarter of 2014. The adoption of this accounting guidance had no impact on our consolidated results.
	In July 2013, the FASB issued Accounting Standards Update (“ASU”) No. 2013-011, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. This ASU provides specific guidance on financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The new guidance applies to all entities with unrecognized tax benefits that also have tax loss or tax credit carryforwards in the same tax jurisdiction as of the reporting date and states that an unrecognized tax benefit in those circumstances should be presented as a reduction to the deferred tax asset. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013 and we adopted the new guidance prospectively in the first quarter of 2014. The adoption of this accounting guidance resulted in the reclassification, for presentation purposes only, of approximately $4 million from other liabilities to deferred tax assets in our consolidated balance sheet as of March 31, 2014.

Business_Combinations

Business Combinations	3 Months Ended
	Mar. 31, 2014
Business Combinations [Abstract]	'
Business Combinations	'
	2. Business Combinations
	Acquisition of dbMotion Ltd.
	On March 4, 2013, we acquired all of the issued and outstanding share capital of dbMotion Ltd. (“dbMotion”), a leading supplier of community health solutions.
	Under the acquisition method of accounting, the fair value of consideration transferred was allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date with the remaining unallocated amount recorded as goodwill. During the three months ended March 31, 2014, we finalized the allocation of the fair value of the consideration transferred, which resulted in an increase of approximately $1.0 million in both the total fair value of consideration transferred and the residual allocation to goodwill.
	The total fair value of consideration transferred for the dbMotion acquisition is comprised of the following:
		(In thousands)
	Cash	$	140,079
	Allscripts common stock, 3,823,453 shares, par value $0.01 per share, fair value at closing $12.57 per share		48,061
	Deferred cash consideration payable on the 18-month anniversary of the closing		23,023
	Subordinated promissory note maturing 18 months following the closing		6,648
	Fair value of Allscripts’ previous interest in dbMotion		8,367
	Total fair value of consideration transferred	$	226,178
	The allocation of the fair value of the consideration transferred, including all measurement period adjustments, is as follows:
		(In thousands)
	Acquired cash and cash equivalents, and restricted cash	$	14,188
	Accounts receivable, net		3,226
	Prepaid expenses and other current assets		574
	Fixed assets and other long-term assets		1,449
	Goodwill		137,649
	Intangible assets		85,450
	Accounts payable and accrued liabilities		(10,560	)
	Deferred taxes, net		(36	)
	Deferred revenue		(5,100	)
	Other liabilities		(662	)
	Net assets acquired	$	226,178
	Acquisition costs related to the dbMotion acquisition totaled approximately $1.8 million and $1.4 million for the three months ended March 31, 2014 and 2013, respectively, and are included in selling, general and administrative expenses. These costs include employee compensation costs of approximately $1.8 million and $0.5 million during the three months ended March 31, 2014 and 2013, respectively. During the three months ended March 31, 2013, we also incurred $0.5 million of seller transaction costs. Additional employee compensation of approximately $1.4 million related to the dbMotion acquisition is expected to be incurred during the remainder of 2014.
	The revenue and net loss of dbMotion since March 4, 2013 that are included in our consolidated statement of operations for the three months ended March 31, 2013, and the supplemental pro forma revenue and net loss of the combined entity, are as follows:
	(In thousands)	Three Months
		Ended
		March 31,
		2013
		(Unaudited)
	Actual from dbMotion since acquisition date of March 4, 2013:
	Revenue	$	174
	Net loss	($	2,847	)
	Supplemental pro forma data for combined entity:
	Revenue	$	348,260
	Net loss	($	23,014	)
	Net loss per share, basic and diluted	($	0.13	)
	The unaudited supplemental pro forma data has been calculated after applying our accounting policies and adjusting the results of dbMotion to reflect the additional depreciation and amortization that would have been charged assuming the fair value adjustments to property, plant and equipment and intangible assets had been applied on January 1, 2012, together with the consequential tax effects. Supplemental pro forma results for the three months ended March 31, 2013 were adjusted to exclude acquisition-related costs incurred during the period as well as the nonrecurring gain related to the fair value adjustment of our prior cost method investment in dbMotion. The effects of transactions between us and dbMotion during the period presented have been eliminated.
	Amortization of software development costs and acquisition-related assets in our consolidated statement of operations for the three months ended March 31, 2013 includes approximately $1.2 million related to the acquisition of dbMotion, which is attributable to cost of revenue as follows: approximately $0.4 million related to system sales, approximately $0.6 million related to professional services, and approximately $0.2 million related to maintenance.
	Acquisition of Jardogs LLC
	Also on March 4, 2013, we acquired substantially all of the assets of Jardogs LLC (Jardogs), the developer of FollowMyHealth, a highly-rated, cloud-based patient engagement solution provider, for $24 million in cash. During the three months ended March 31, 2014, we finalized the allocation of the Jardogs purchase price, resulting in no additional measurement period adjustments to the fair values of the assets and liabilities acquired as disclosed in our Form 10-K.
	The pro forma impact of the Jardogs acquisition on current and prior quarters, as well as the net revenues and operating losses generated by Jardogs subsequent to its acquisition for the three months ended March 31, 2013, are not material. Acquisition and integration-related costs related to the Jardogs acquisition are included in selling, general and administrative expenses for the three months ended March 31, 2013 and totaled approximately $0.7 million.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	3. Fair Value Measurements
	Fair value measurements are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market assumptions in the absence of observable market information. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. The fair values of assets and liabilities required to be measured at fair value are categorized based upon the level of judgment associated with the inputs used to measure their value in one of the following three categories:
	Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date. Our Level 1 investments include money market funds valued daily by the fund companies, and the valuation is based on the publicly reported net asset value of each fund.
	Level 2: Inputs, other than quoted prices included in Level 1, are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar instruments in active markets, and inputs other than quoted prices that are observable for the asset or liability. Our Level 2 non-derivative investments include marketable securities and consist of mortgage and asset-backed bonds. Marketable securities are recorded at fair value determined using a market approach, based on prices and other relevant information generated by market transactions involving identical or comparable assets which are considered to be Level 2 inputs. Our Level 2 derivative financial instrument is an interest rate swap contract which is valued based upon observable values for underlying interest rates and market determined risk premiums.
	Level 3: Inputs are unobservable for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. Our Level 3 financial instruments include derivative financial instruments comprising the 1.25% Call Option asset and the embedded conversion option liability. Refer to Note 7, “Debt,” and Note 9, “Derivative Financial Instruments,” for further information, including defined terms, regarding our derivative financial instruments. These derivatives are not actively traded and are valued based on an option pricing model that uses observable and unobservable market data for inputs. Significant market data inputs used to determine fair value as of March 31, 2014 included our common stock price, time to maturity of the derivative instruments, the risk-free interest rate, and the implied volatility of our common stock. The 1.25% Call Option asset and the embedded cash conversion option liability were designed with the intent that changes in their fair values would substantially offset, with limited net impact to our earnings. Therefore, the sensitivity of changes in the unobservable inputs to the option pricing model for such instruments is substantially mitigated.
	The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates:
		Balance Sheet	March 31, 2014											December 31, 2013
	(In thousands)	Classifications	Level 1		Level 2			Level 3			Total			Level 1		Level 2			Level 3			Total
	Money market funds	Cash equivalents	$	0	$	0		$	0		$	0		$	3,634	$	0		$	0		$	3,634
	Marketable securities	Long-term marketable securities		0		1,313			0			1,313			0		1,329			0			1,329
	1.25% Call Option	Other assets		0		0			134,600			134,600			0		0			104,656			104,656
	Cash conversion option	Other liabilities		0		0			(135,637	)		(135,637	)		0		0			(105,637	)		(105,637	)
	Interest rate swap	Other liabilities		0		(292	)		0			(292	)		0		(458	)		0			(458	)
	Total		$	0	$	1,021		($	1,037	)	($	16	)	$	3,634	$	871		($	981	)	$	3,524
	During the three months ended March 31, 2014, we acquired certain non-marketable equity securities of a third party and entered into a commercial agreement with the third party to license and distribute its products and services for total consideration of approximately $6.0 million. The equity investment and commercial agreement were valued at approximately $4.1 million and $1.9 million, respectively. The equity investment is recorded at cost and is included in other assets, and the commercial agreement is included in intangible assets, net, in the accompanying consolidated balance sheet as of March 31, 2014. As of December 31, 2013, our outstanding investments in non-marketable equity securities were not material.
	Our long-term financial liabilities include amounts outstanding under our senior secured credit facility, with carrying values that approximate fair value since the interest rates approximate current market rates. In addition, the carrying amount of our 1.25% Cash Convertible Senior Notes (the “1.25% Notes”) approximates fair value as of March 31, 2014, since the effective interest rate on the 1.25% Notes approximates current market rates. See Note 7, “Debt,” for further information regarding our long-term financial liabilities.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Stockholders' Equity	'
	4. Stockholders’ Equity
	Stock-based Awards
	We measure stock-based compensation expense at the grant date based on the fair value of the award. We recognize the expense for service-based share awards over the appropriate service period on a straight-line basis, net of estimated forfeitures. We recognize the expense for performance-based and market-based share awards over the vesting period under the accelerated attribution method, net of estimated forfeitures. In addition, we recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved.
	The fair value of service-based restricted stock units and restricted stock awards is measured at their underlying closing share price on the date of grant. The fair value of market-based restricted stock units is measured using the Monte Carlo pricing model. The fair value of stock options granted during the three months ended March 31, 2013 was determined using the Black-Scholes-Merton valuation model and reflects the below input assumptions. No stock options were granted during the three months ended March 31, 2014.
		Three Months Ended March 31, 2013
	Weighed-average exercise price	$	12.72
	Expected term ( in years)		4.75
	Expected volatility		55.9	%
	Expected dividend yield		0	%
	Risk-free interest rate		0.8	%
	Stock-based compensation expense recognized during the three months ended March 31, 2014 and 2013 is included in our consolidated statements of operations as follows:
		Three Months Ended March 31,
	(In thousands)	2014			2013
	Cost of revenue:
	Professional services	$	606		$	577
	Maintenance		330			381
	Transaction processing and other		402			424
	Total cost of revenue		1,338			1,382
	Selling, general and administrative expenses		6,178			4,726
	Research and development		2,554			1,896
	Total stock-based compensation expense	$	10,070		$	8,004
	No stock-based compensation costs were capitalized during the three months ended March 31, 2014 and 2013.
	We granted stock-based awards as follows:
		Three Months Ended March 31, 2014
	(In thousands, except per share amounts)	Shares			Weighted-Average
					Grant Date
					Fair Value
	Service-based restricted stock units		1,302		$	18.47
	Performance-based restricted stock units with a service condition		467		$	18.51
	Market-based restricted stock units with a service condition		221		$	14.36
			1,990		$	18.03
	During the three months ended March 31, 2014 and the year ended December 31, 2013, approximately 0.6 million and 2.6 million shares of stock, respectively, were issued in connection with the exercise of options and the release of restrictions on stock awards.
	Stock Repurchases
	In April 2011, the Board of Directors of Allscripts Healthcare Solutions, Inc. (the “Board”) approved a stock repurchase program under which we may purchase up to $200 million of our common stock over three years expiring on May 9, 2014 or such earlier time that the total dollar amount authorized by these resolutions has been used. In April 2012, the Board approved the repurchase of an additional $200 million, bringing the total repurchase authorization to $400 million. Any share repurchase transactions may be made through open market transactions, block trades, privately negotiated transactions (including accelerated share repurchase transactions) or other means. Any repurchase activity will depend on factors such as our working capital needs, cash requirements for investments, debt repayment obligations, our stock price, and economic and market conditions. Our stock repurchase program may be accelerated, suspended, delayed or discontinued at any time.
	No shares were repurchased under this program during the three months ended March 31, 2014 and the year ended December 31, 2013. As of March 31, 2014, the amount available for repurchase of our common stock under this program was approximately $123 million.
	Net Share-settlements
	Beginning in 2011, upon vesting, restricted stock units and awards are generally net share-settled to cover the required withholding tax and the remaining amount is converted into an equivalent number of shares of common stock. The majority of restricted stock units and awards that vested in 2014 and 2013 were net-share settled such that we withheld shares with value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. Total payments for the employees’ minimum statutory tax obligations to the taxing authorities are reflected as a financing activity within the accompanying consolidated statements of cash flows. The total shares withheld for the three months ended March 31, 2014 and 2013 were 174 thousand and 125 thousand, respectively, and were based on the value of the restricted stock units and awards on their vesting date as determined by our closing stock price. These net-share settlements had the effect of share repurchases by us as they reduced the number of shares that would have otherwise been issued as a result of the vesting.
	Issuance of Warrants
	In June 2013, we agreed to issue a warrant to a commercial partner as part of an overall commercial relationship pursuant to which the warrant holder has the right to purchase 1.5 million shares of our common stock at a strike price of $12.94 per share. The warrant vests in four equal annual installments of 375 thousand shares (beginning in June 2014) and expires in June 2020. Our issuance of the warrant was a private placement exempt from registration pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended. This warrant is not actively traded and is valued based on an option pricing model that uses observable and unobservable market data for inputs. During the three months ended March 31, 2014, we recognized approximately $0.6 million of the warrant fair value as a reduction to transaction processing and other revenues.

Earnings_Loss_Per_Share

Earnings (Loss) Per Share	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Earnings (Loss) Per Share	'
	5. Earnings (Loss) Per Share
	Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average shares of common stock outstanding and dilutive common stock equivalents. Dilutive common stock equivalents consist of stock options, restricted stock unit awards and warrants calculated under the treasury stock method.
	The calculations of earnings (loss) per share are as follows:
		Three Months Ended March 31,
	(In thousands, except per share amounts)	2014			2013
	Basic Loss per Common Share:
	Net loss	($	20,742	)	($	11,592	)
	Net loss available to common stockholders	($	20,742	)	($	11,592	)
	Weighted-average common shares outstanding		179,033			173,710
	Basic Loss per Common Share	($	0.12	)	($	0.07	)
	Diluted Loss per Common Share:
	Net loss	($	20,742	)	($	11,592	)
	Net loss available to common stockholders	($	20,742	)	($	11,592	)
	Weighted-average common shares outstanding		179,033			173,710
	Dilutive effect of stock options, restricted stock unit awards and warrants		0			0
	Weighted-average common shares outstanding assuming dilution		179,033			173,710
	Diluted Loss per Common Share	($	0.12	)	($	0.07	)
	As a result of our net loss available to common stockholders for the three months ended March 31, 2014 and 2013, we used basic weighted-average common shares outstanding in the calculation of diluted loss per share for each of these periods, since the inclusion of any stock equivalents would be anti-dilutive.
	The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted (loss) earnings per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive:
		Three Months Ended March 31,
	(In thousands)	2014			2013
	Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation		21,721			3,668

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets	'
	6. Goodwill and Intangible Assets
	Goodwill and intangible assets consist of the following:
		March 31, 2014							December 31, 2013
	(In thousands)	Gross		Accumulated			Intangible		Gross		Accumulated			Intangible
		Carrying		Amortization			Assets,  Net		Carrying		Amortization			Assets,  Net
		Amount							Amount
	Intangibles subject to amortization
	Proprietary technology	$	445,960	($	240,548	)	$	205,412	$	445,960	($	231,634	)	$	214,326
	Customer contracts and relationships		544,073		(359,432	)		184,641		542,205		(352,560	)		189,645
	Total	$	990,033	($	599,980	)	$	390,053	$	988,165	($	584,194	)	$	403,971
	Intangibles not subject to amortization
	Registered trademarks						$	52,000						$	52,000
	Goodwill							1,190,603							1,189,585
	Total						$	1,242,603						$	1,241,585
	During the three months ended March 31, 2014, we finalized the allocation of the dbMotion and Jardogs acquisition prices, which resulted in the recognition of additional goodwill. Refer to Note 2, “Business Combinations” for additional information regarding these acquisitions and the measurement period adjustment recorded during the three months ended March 31, 2014. Changes in the carrying amounts of goodwill by reportable segment for the three months ended March 31, 2014 were as follows:
	(In thousands)	Clinical and		Population			Managed		Total
		Financial  Solutions		Health			Services
	Balance as of December 31, 2013	$	625,769	$	425,216		$	138,600	$	1,189,585
	Additions arising from business acquisitions:
	dbMotion		0		1,018			0		1,018
	Total additions to goodwill		0		1,018			0		1,018
	Impairment of goodwill		0		0			0		0
	Balance as of March 31, 2014	$	625,769	$	426,234		$	138,600	$	1,190,603
	There were no accumulated impairment losses associated with our goodwill as of March 31, 2014 or December 31, 2013.

Debt

Debt	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Debt	'
	7. Debt
	Debt outstanding, excluding capital leases, consisted of the following:
			March 31, 2014						December 31, 2013
	(In thousands)		Principal		Unamortized		Net		Principal		Unamortized		Net
			Balance		Discount		Carrying		Balance		Discount		Carrying
							Amount						Amount
	1.25% Cash Convertible Senior Notes		$	345,000	$	75,014	$	269,986	$	345,000	$	77,529	$	267,471
	Senior Secured Credit Facilities (long-term portion)			261,875		2,106		259,769		280,000		2,338		277,662
	Senior Secured Credit Facilities (current portion)			19,688		963		18,725		16,875		982		15,893
	Total debt		$	626,563	$	78,083	$	548,480	$	641,875	$	80,849	$	561,026
	Interest expense consisted of the following:
			Three Months Ended March 31,
	(In thousands)		2014		2013
	Interest expense		$	3,957	$	3,337
	Amortization of discounts			2,766		0
	Amortization of debt issuance costs			510		1,300
	Total interest expense		$	7,233	$	4,637
	Interest expense related to the 1.25% Notes was comprised of the following:
			Three Months Ended March 31,
	(In thousands)		2014		2013
	Coupon interest at 1.25%		$	1,078	$	0
	Amortization of original issuance discount			2,515		0
	Amortization of debt issuance costs			295		0
	Total interest expense related to the 1.25% Notes		$	3,888	$	0
	There have been no significant changes in our senior secured credit facility agreement from those disclosed in our Form 10-K. As of March 31, 2014, the if-converted value of the 1.25% Notes exceeded the principal amount, as the closing price of our common stock as of such date ($18.03) exceeded the conversion price of the 1.25% Notes (approximately $17.19).
	As of March 31, 2014, $216.6 million under a term loan, $65.0 million under a revolving credit facility, and $1.1 million in letters of credit were outstanding under our senior secured credit facility. As of March 31, 2014, the interest rate on the senior secured credit facility was LIBOR plus 2.75%, which totaled 2.90%. Refer to Note 9, “Derivative Financial Instruments,” for a discussion of our interest rate swap agreement. We were in compliance with all covenants under our senior secured credit facility agreement as of March 31, 2014. Unamortized deferred debt issuance costs total $11.0 million and are included within other assets on the consolidated balance sheet as of March 31, 2014.
	As of March 31, 2014, we had $358.9 million available, net of outstanding letters of credit, under our revolving credit facility. There can be no assurance that we will be able to draw on the full available balance of our senior secured credit facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings.
	The following table summarizes our future payment obligations under the 1.25% Notes and the senior secured credit facility as of March 31, 2014:
	(Dollar amounts in thousands)		Total		Remainder of		2015		2016		2017		2018		Thereafter
					2014
	1.25% Cash Convertible Senior Notes (1)		$	345,000	$	0	$	0	$	0	$	0	$	0	$	345,000
	Senior Secured Term Loan			216,563		14,063		28,125		39,375		50,625		84,375		0
	Senior Secured Revolving Facility			65,000		0		0		0		0		65,000		0
			$	626,563	$	14,063	$	28,125	$	39,375	$	50,625	$	149,375	$	345,000
	-1	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	8. Income Taxes
	The provision for income taxes reflects our estimate of the effective tax rate expected to be applicable for the full year. To the extent that actual pre-tax results for the year differ from the forecasted estimates applied at the end of the most recent interim period, the actual tax rate recognized during calendar 2014 could be different from the forecast rate. Our provision for income taxes differs from the tax computed at the U.S. federal statutory income tax rate due primarily to valuation allowance, income attributable to foreign jurisdictions taxed at lower rates, state taxes, permanent differences, and certain discrete items. The effective tax rates were as follows:
		Three Months Ended March 31,
	(Dollar amounts in thousands)	2014			2013
	Loss before income taxes	($	19,176	)	($	24,789	)
	Income tax (provision) benefit	($	1,566	)	$	13,197
	Effective tax rate		(8.2	%)		53.2	%
	Our effective tax rate for the three months ended March 31, 2014 is lower compared with the prior year comparable period primarily due to the impact of an approximately $10 million valuation allowance recorded in the three months ended March 31, 2014 against federal net operating loss and credit carryforwards. In addition, the U.S. research and development credit had not been extended as of March 31, 2014 for the tax year 2014 and, therefore, no estimate for this credit has been included in the effective tax rate as of March 31, 2014; whereas, in the three months ended March 31, 2013, impacts for both the 2012 and 2013 credits were included in the tax benefit recorded.
	In evaluating our ability to recover our deferred tax assets within the jurisdictions from which they arise, we consider all available evidence, including scheduled reversals of deferred tax liabilities, tax-planning strategies, and results of recent operations. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). The additional valuation allowance recorded in the three months ended March 31, 2014 related to deferred tax assets associated with net operating loss carryforwards.
	Our unrecognized income tax benefits were $18.2 million and $18.3 million as of March 31, 2014 and December 31, 2013, respectively, the decrease being primarily attributable to a settlement with a taxing authority. If any portion of our unrecognized tax benefits is recognized, it could impact our effective tax rate. The tax reserves are reviewed periodically and adjusted in light of changing facts and circumstances, such as progress of tax audits, lapse of applicable statutes of limitations, and changes in tax law.

Derivative_Financial_Instrumen

Derivative Financial Instruments	3 Months Ended
	Mar. 31, 2014
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'
Derivative Financial Instruments	'
	9. Derivative Financial Instruments
	1.25% Call Option
	Concurrent with the issuance of the 1.25% Notes in June 2013, we entered into privately negotiated hedge transactions with certain of the initial purchasers of the 1.25% Notes (collectively, the “1.25% Call Option”). Assuming full performance by the counterparties, the 1.25% Call Option is intended to offset cash payments in excess of the principal amount due upon any conversion of the 1.25% Notes.
	The 1.25% Call Option, which is indexed to our common stock, is a derivative asset that requires mark-to-market accounting treatment due to the cash settlement features until the 1.25% Call Option settles or expires. The 1.25% Call Option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the 1.25% Call Option, refer to Note 3, “Fair Value Measurements.” The fair value of the 1.25% Call Option at March 31, 2014 and December 31, 2013 was approximately $134.6 million and $104.7 million, respectively.
	The 1.25% Call Option does not qualify for hedge accounting treatment. Therefore, the change in fair value of these instruments is recognized immediately in our consolidated statements of operations in other (expense) income, net. For the three months ended March 31, 2014, the change in the fair value of the 1.25% Call Option resulted in a gain of $29.9 million. Because the terms of the 1.25% Call Option are substantially similar to those of the 1.25% Notes embedded cash conversion option, discussed below, we expect the net effect of those two derivative instruments on our earnings to be minimal.
	1.25% Notes Embedded Cash Conversion Option
	The embedded cash conversion option within the 1.25% Notes is required to be separated from the 1.25% Notes and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of operations in other (expense) income, net until the cash conversion option settles or expires. The initial fair value liability of the embedded cash conversion option was $82.8 million, which simultaneously reduced the carrying value of the 1.25% Notes (effectively an original issuance discount). The embedded cash conversion option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the embedded cash conversion option, refer to Note 3, “Fair Value Measurements.” The fair value of the embedded cash conversion option at March 31, 2014 and December 31, 2013 was approximately $135.6 million and $105.6 million, respectively. For the three months ended March 31, 2014, the change in the fair value of the embedded cash conversion option resulted in a loss of $30.0 million. This loss was slightly higher than the gain recognized on the 1.25% Call Option over the same period.
	Interest Rate Swap Agreement
	We entered into an interest rate swap agreement with an effective date of October 29, 2010 that has the economic effect of modifying the variable rate component of the interest obligations associated with a portion of our variable rate debt. The initial notional amount of the interest rate swap agreement was $300 million, with scheduled step downs over time, and an expiration date of October 31, 2014. At March 31, 2014, the notional amount of the interest rate swap agreement was $100 million. The interest rate swap agreement converts the one-month LIBOR rate on the corresponding notional amount of debt to an effective fixed rate of 0.896% (exclusive of the applicable margin currently charged under the Senior Secured Credit Facility). The critical terms of the interest rate swap agreement and the related debt agreement match and allow us to designate the interest rate swap agreement as a highly effective cash flow hedge under GAAP. The interest rate swap agreement is designed to protect us against changes in interest payments due to benchmark interest rate movements. The change in fair value of this interest rate swap agreement is recognized in other comprehensive (loss) income with the corresponding amounts included in other assets or other liabilities in our consolidated balance sheets. Amounts accumulated in other comprehensive income (loss) are indirectly recognized in earnings as periodic settlements of the swap occur and the fair value of the swap declines to zero as it nears expiration.
	The fair value of our interest rate swap was a liability of approximately $0.3 million and $0.5 million at March 31, 2014 and December 31, 2013, respectively. We recognized the following activity related to our interest rate swap agreement:
		Three Months Ended March 31,
	(In thousands)	2014			2013
	Effective Portion
	Current period increase in fair value recognized in OCI	$	166		$	353
	Tax effect		(66	)		(136	)
	Net	$	100		$	217
	Loss reclassified from OCI to interest expense	$	199		$	359
	Amount excluded from Effectiveness Assessment and Ineffective Portion Gain (loss) recognized in other income (expense)	$	0		$	0
	We estimate that approximately $0.3 million of derivative losses included in other comprehensive income (“OCI”) will be reclassified into earnings within the next 7 months. This amount has been calculated assuming the variable effective interest rate 2.90% as of March 31, 2014 remains the same through the next 7 months. No gains (losses) were reclassified from OCI into earnings as a result of forecasted transactions that failed to occur during the three months ended March 31, 2014 and 2013.

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Contingencies	'
	10. Contingencies
	In addition to commitments and obligations in the ordinary course of business, we are currently subject to various legal proceedings and claims that have not been fully adjudicated, certain of which are discussed below. We intend to vigorously defend ourselves in these matters.
	No less than quarterly, we review the status of each significant matter and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made. Furthermore, the outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. If one or more of these legal proceedings were resolved against us in a reporting period for amounts in excess of our management’s expectations, our consolidated financial statements for that reporting period could be materially adversely affected. Additionally, the resolution of a legal proceeding against us could prevent us from offering our products and services to current or prospective clients, which could further adversely affect our operating results.
	In the opinion of our management, based on the information currently available, we do not believe a material risk of loss in excess of amounts recorded is at least reasonably possible with respect to the following matters.
	On September 14, 2010, Pegasus Imaging Corporation (“Pegasus”) filed suit against us in the Circuit Court of the Thirteenth Judicial Circuit of the State of Florida in and for Hillsborough County, Florida, which we transferred to the Special Superior Court for Complex Business Cases. The lawsuit also named former officers Jeffrey Amrein and John Reinhart as defendants. The amended complaint added two defunct Florida corporations that did business with us, and asserted causes of action against defendants for fraudulent misrepresentations, negligent misrepresentations, and deceptive and unfair trade practices under Florida law, allegedly arising from previous business dealings between Pegasus and Advanced Imaging Concepts, Inc., a software company based in Louisville, Kentucky that we purchased in August 2003, and from our testing of a software development toolkit pursuant to a free trial license from Pegasus in approximately 1999. On April 16, 2013, Plaintiff filed a Second Amended Complaint adding claims against us for breach of contract, fraud, and negligence. On June 27, 2013, we filed our First Amended Answer, Defenses, and Counterclaims to Plaintiff’s Second Amended Complaint, denying all material allegations, and asserting counterclaims against Pegasus for breach of two license agreements, breach of warranty, breach of a settlement and arbitration agreement, and three counts of negligent misrepresentation. Mediation is currently scheduled for June 2014. The case is currently scheduled for trial in November 2014.
	On December 27, 2012, Pain Clinic of Northwest Florida, Inc. filed a complaint in the Circuit Court of the 11th Judicial Circuit in and for Miami-Dade County, Florida, against us. On January 29, 2013, a First Amended Complaint was filed in this lawsuit through which American Pain Care Specialists, LLC, Advanced Pain Specialists, Inc., and South Baldwin Family Practice, LLC were added as additional plaintiffs. The plaintiffs are currently seeking to certify a class of all similarly situated physician-clients that purchased MyWay and seek damages for various claims, including breach of warranty and unjust enrichment. On May 6, 2013, the plaintiffs filed a Second Amended Complaint, in which the plaintiffs dropped the claim for breach of warranty, and added claims for tortious interference with business relationships, violations of Florida’s Deceptive and Unfair Trade Practices Act, and violations of various other states’ consumer protection laws. On April 21, 2014, the plaintiffs filed a Third Amended Complaint, in which Manhattan Podiatry Associates, P.C. and Ritchken & First Medical Group were added as additional plaintiffs. In the Third Amended Complaint, plaintiffs dropped the claims for tortious interference and all violations of other states’ consumer protection laws, other than those of New York and California. Discovery is proceeding. No trial date has been scheduled.
	On January 30, 2013, Costco Wholesale Corporation made a demand for arbitration against us with the International Institute for Conflict Resolution in connection with our offer to upgrade our MyWay clients to Professional Suite. The demand for arbitration seeks certain equitable relief in connection with the upgrade offer and also seeks damages for breach of contract and breach of an alleged duty of good faith and fair dealing. Arbitration has been scheduled for October 2014.
	On February 26, 2013, a lawsuit was filed by Cardinal Health 200, LLC against us in the Court of Common Pleas for Franklin County, Ohio. The complaint seeks damages of no less than $3,978,000 for alleged breaches of contract by us in connection with our offer to upgrade our MyWay clients to Professional Suite, as well as other equitable relief. The complaint alternatively seeks a declaration that we invalidly terminated our agreement with the plaintiff. No trial date has been scheduled.
	On August 7, 2013, we filed a demand for arbitration against Etransmedia Technology, Inc. (“Etransmedia”) with the American Arbitration Association, seeking relief for breach of contract and also equitable relief with respect to the release of certain data held by Etransmedia in its hosted facilities. Etransmedia has asserted counterclaims against us related to our offer to upgrade MyWay clients who were hosted by Etransmedia to Professional Suite, including fraud, deceptive trade practices under the North Carolina Uniform Deceptive Trade Practices Act, breach of contract, breach of express warranty, negligent misrepresentation, unjust enrichment, declaratory judgment, and tortious interference with contract and prospective contract. Discovery is proceeding. Arbitration has been scheduled for June 2014.
	In the opinion of our management, there is a reasonable possibility that we may incur losses with respect to the following matters. However, given the current early stage of the matters, it is not possible to estimate the possible loss or range of loss at this time. Our management will continue to evaluate the potential exposure related to these matters in future periods.
	On May 1, 2012, Physicians Healthsource, Inc. filed a class action complaint in U.S. District Court for the Northern District of Illinois against us. The complaint alleges that on multiple occasions between July 2008 and December 2011, we or our agent sent advertisements by fax to the plaintiff and a class of similarly situated persons, without first receiving the recipients’ express permission or invitation in violation of the Telephone Consumer Protection Act, 47 U.S.C. § 227 (the “TCPA”). The plaintiff seeks $500 for each alleged violation of the TCPA; treble damages if the Court finds the violations to be willful, knowing or intentional; and injunctive and other relief. Discovery is proceeding. No trial date has been scheduled.
	On May 2, 2012, a lawsuit was filed in the United States District Court for the Northern District of Illinois against us; Glen Tullman, our former Chief Executive Officer; and William Davis, our former Chief Financial Officer, by the Bristol County Retirement System for itself and on behalf of a purported class consisting of stockholders who purchased our common stock between November 18, 2010 and April 26, 2012. The plaintiffs allege that we, Mr. Tullman and Mr. Davis made materially false and misleading statements and/or omissions during the putative class period regarding our progress in integrating our and Eclipsys’ businesses following their August 24, 2010 merger, and that we lacked a reasonable basis for certain statements regarding our post-merger integration efforts, operations, results and projections of future financial performance. A fully-briefed motion to dismiss is pending. No trial date has been scheduled.
	On June 27, 2012, a purported shareholder, Richard Devereaux, filed a shareholder derivative action in the Circuit Court of Cook County, Illinois against us; Glen Tullman, our former Chief Executive Officer; William Davis, our former Chief Financial Officer; Paul Black, our current Chief Executive Officer and a current member of the Board; and Dennis Chookaszian, Robert Cindrich, Marcel Gamache, Philip Green, and Michael Kluger, each of whom are or were members of the Board. The suit alleges breach of fiduciary duties and unjust enrichment against certain of our former and current executives who allegedly made misleading claims about our business and financial condition, which allegedly caused our stock price to be artificially inflated and then drop sharply when we reported earnings below expectations and disclosed a “leadership dispute” in a regulatory filing. The case is currently stayed by agreement of the parties.

Business_Segments

Business Segments	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Business Segments	'
	11. Business Segments
	We primarily derive our revenues from sales of our proprietary software and related hardware, professional services and IT outsourcing services. These sales are also the basis for our recurring service contracts for software maintenance and certain transaction processing services. We revised our reportable segments effective December 1, 2013, in connection with changes to our organizational and management structure that were announced earlier in 2013. Prior to this change, we used five reportable segments: Software Delivery, Services Delivery, Client Support, Pathway Solutions and IT Outsourcing.
	The changes to our organizational and management structure were aimed at improving our operational effectiveness, enhancing our competitiveness and creating a greater focus on client needs. These changes, which involved the creation of strategic business units, were designed to transition us towards a flatter business unit model aligned with key products and services, and away from a functional organization. After the finalization of these changes and based upon the information used by our Chief Operating Decision Maker (our “CODM”) for making operating decisions and assessing performance, we identified nine operating segments, which were aggregated into three reportable segments: Clinical and Financial Solutions, Population Health, and Managed Services.
	The Clinical and Financial Solutions segment includes our Acute, TouchWorks, Professional Practices, Payer and Life Sciences, and International strategic business units. This segment derives its revenue from the sale of integrated clinical software applications, financial and information solutions, and related installation and maintenance services, to physician practices, hospitals and health systems of various sizes. These solutions primarily include Electronic Health Record-related software, financial and practice management software, related installation and training services, and electronic claims administration services. The Population Health segment includes our Performance and Care Logistics and Population Health strategic business units. This segment derives its revenue from the sale of health management solutions, which are mainly targeted at hospitals, health systems and Accountable Care Organizations, and which enable such organizations to connect, transition, analyze, and coordinate care across the entire care community. The Managed Services segment includes our Outsourcing and Remote Hosting strategic business units. It derives its revenue from the sale of outsourcing solutions, where we assume partial to total responsibility for a healthcare organization’s IT operations, and remote hosting solutions. The revenues from this segment are primarily reflected as part of transaction processing and other in our consolidated statements of operations. Segment data for prior periods presented in the table below has been restated to conform to the current year’s presentation.
	Our CODM uses segment revenues, gross profit and income from operations as measures of performance and to allocate resources. In determining revenue, gross profit and income from operations for our segments, we do not include in revenue the amortization of acquisition-related deferred revenue adjustments, which reflect the fair value adjustments to deferred revenue acquired in a business acquisition; and we exclude the amortization of intangible assets, stock-based compensation expense, non-recurring expenses and transaction-related costs, and non-cash asset impairment charges from the operating segment data provided to our CODM. Non-recurring expenses relate to certain severance, product consolidation, legal, consulting, and other charges incurred in connection with activities that are considered one-time. Accordingly, these amounts are not included in our reportable segment results and are included in an “Unallocated Amounts” category within our segment disclosure. The “Unallocated Amounts” category also includes corporate general and administrative expenses (including marketing expenses), which are centrally managed. In addition, the “Unallocated Amounts” category includes revenue and the associated cost from the resale of certain ancillary products, primarily consisting of hardware. We do not track our assets by segment.
		Three Months Ended March 31,
	(In thousands)	2014			2013
	Revenue:
	Clinical and Financial Solutions	$	205,386		$	217,943
	Population Health		70,028			60,529
	Managed Services		61,921			59,732
	Unallocated Amounts		2,950			8,862
	Total revenue	$	340,285		$	347,066
	Gross Profit:
	Clinical and Financial Solutions	$	99,032		$	101,590
	Population Health		48,694			37,840
	Managed Services		5,728			7,555
	Unallocated Amounts		(15,268	)		(12,557	)
	Total gross profit	$	138,186		$	134,428
	Income (Loss) from operations:
	Clinical and Financial Solutions	$	43,215		$	42,577
	Population Health		24,279			21,115
	Managed Services		5,728			7,555
	Unallocated Amounts		(85,133	)		(99,530	)
	Total loss from operations	($	11,911	)	($	28,283	)

North_American_Site_Consolidat

North American Site Consolidation Plan	3 Months Ended
	Mar. 31, 2014
Restructuring And Related Activities [Abstract]	'
North American Site Consolidation Plan	'
	12. North American Site Consolidation Plan
	On February 18, 2013, we announced a North American site consolidation plan (the “Site Consolidation Plan”) designed to create a more simplified and efficient organization that is aligned more closely with our business priorities. The Site Consolidation Plan included the closing of twelve offices and one warehouse. We are also implementing changes to corporate operating models intended to reduce costs associated with product solutions development. The costs of implementing these changes primarily consist of employee severance and relocation costs, and lease exit costs.
	During the three months ended March 31, 2014, we recognized a benefit of approximately $2.0 million due to the release of previously accrued severance costs which we no longer expect to pay, while during the three months ended March 31, 2013, we incurred approximately $11.0 million in costs resulting from the Site Consolidation Plan. These amounts are included in selling, general and administrative expenses in our consolidated statements of operations for the three months ended March 31, 2014 and 2013, respectively. The majority of the benefit realized and expenses incurred during the three months ended March 31, 2014 and 2013, respectively, related to severance, retention bonuses and relocation expenses. The portion of these amounts allocable to our reportable segments is not material. In the first quarter of 2013, we established a liability for approximately $11.2 million for severance costs resulting from the Site Consolidation Plan of which approximately $4.2 million remained as of December 31, 2013. During the three months ended March 31, 2014, we paid approximately $1.0 million and released approximately $2.0 million of previously accrued severance costs, which we no longer expect to pay, resulting in a remaining liability of approximately $1.2 million, which is included in accrued compensation and benefits in our consolidated balance sheet as of March 31, 2014.
	Additional estimated costs yet to be incurred in connection with the Site Consolidation Plan primarily include lease exit costs of approximately $1.0 million. This amount is an estimate, and actual charges may vary materially based on the timing and amount of sublease income and other related expenses and changes in management’s assumptions. We expect to complete the Site Consolidation Plan and incur all remaining related costs by the end of 2014.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” or “our” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries, unless otherwise stated.
Unaudited Interim Financial Information	'
	Unaudited Interim Financial Information
	The unaudited interim consolidated financial statements as of and for the three months ended March 31, 2014 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the consolidated financial statements for the periods presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The results of operations for the three months ended March 31, 2014 are not necessarily indicative of the results to be expected for the year ending December 31, 2014.
	Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been omitted in accordance with the SEC’s rules and regulations for interim reporting. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2013 (our “Form 10-K”).
Use of Estimates	'
	Use of Estimates
	The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Actual results could differ materially from these estimates.
Significant Accounting Policies	'
	Significant Accounting Policies
	There have been no changes to our significant accounting policies from those disclosed in our Form 10-K.
Recently Adopted Accounting Pronouncements	'
	Recently Adopted Accounting Pronouncements
	In March 2013, the FASB issued updated authoritative guidance to resolve the diversity in practice about whether FASB Account Standards Codification (“ASC”) Subtopic 810-10, Consolidation—Overall, or ASC Subtopic 830-30, Foreign Currency Matters—Translation of Financial Statements, applies to the release of the cumulative translation adjustment into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business (other than a sale of in substance real estate or conveyance of oil and gas mineral rights) within a foreign entity. In addition, this guidance resolves the diversity in practice for the treatment of business combinations achieved in stages (sometimes also referred to as step acquisitions) involving a foreign entity. This guidance is effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2013 and we adopted the new guidance in the first quarter of 2014. The adoption of this accounting guidance had no impact on our consolidated results.
	In July 2013, the FASB issued Accounting Standards Update (“ASU”) No. 2013-011, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. This ASU provides specific guidance on financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The new guidance applies to all entities with unrecognized tax benefits that also have tax loss or tax credit carryforwards in the same tax jurisdiction as of the reporting date and states that an unrecognized tax benefit in those circumstances should be presented as a reduction to the deferred tax asset. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013 and we adopted the new guidance prospectively in the first quarter of 2014. The adoption of this accounting guidance resulted in the reclassification, for presentation purposes only, of approximately $4 million from other liabilities to deferred tax assets in our consolidated balance sheet as of March 31, 2014.

Business_Combinations_Tables

Business Combinations (Tables)	3 Months Ended
	Mar. 31, 2014
Business Combinations [Abstract]	'
Fair Value of Consideration Transferred for Acquisition	'
	The total fair value of consideration transferred for the dbMotion acquisition is comprised of the following:
		(In thousands)
	Cash	$	140,079
	Allscripts common stock, 3,823,453 shares, par value $0.01 per share, fair value at closing $12.57 per share		48,061
	Deferred cash consideration payable on the 18-month anniversary of the closing		23,023
	Subordinated promissory note maturing 18 months following the closing		6,648
	Fair value of Allscripts’ previous interest in dbMotion		8,367
	Total fair value of consideration transferred	$	226,178
Assets Acquired and Liabilities Assumed	'
	The allocation of the fair value of the consideration transferred, including all measurement period adjustments, is as follows:
		(In thousands)
	Acquired cash and cash equivalents, and restricted cash	$	14,188
	Accounts receivable, net		3,226
	Prepaid expenses and other current assets		574
	Fixed assets and other long-term assets		1,449
	Goodwill		137,649
	Intangible assets		85,450
	Accounts payable and accrued liabilities		(10,560	)
	Deferred taxes, net		(36	)
	Deferred revenue		(5,100	)
	Other liabilities		(662	)
	Net assets acquired	$	226,178
Proforma Results	'
	The revenue and net loss of dbMotion since March 4, 2013 that are included in our consolidated statement of operations for the three months ended March 31, 2013, and the supplemental pro forma revenue and net loss of the combined entity, are as follows:
	(In thousands)	Three Months
		Ended
		March 31,
		2013
		(Unaudited)
	Actual from dbMotion since acquisition date of March 4, 2013:
	Revenue	$	174
	Net loss	($	2,847	)
	Supplemental pro forma data for combined entity:
	Revenue	$	348,260
	Net loss	($	23,014	)
	Net loss per share, basic and diluted	($	0.13	)

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	'
	The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates:
		Balance Sheet	March 31, 2014											December 31, 2013
	(In thousands)	Classifications	Level 1		Level 2			Level 3			Total			Level 1		Level 2			Level 3			Total
	Money market funds	Cash equivalents	$	0	$	0		$	0		$	0		$	3,634	$	0		$	0		$	3,634
	Marketable securities	Long-term marketable securities		0		1,313			0			1,313			0		1,329			0			1,329
	1.25% Call Option	Other assets		0		0			134,600			134,600			0		0			104,656			104,656
	Cash conversion option	Other liabilities		0		0			(135,637	)		(135,637	)		0		0			(105,637	)		(105,637	)
	Interest rate swap	Other liabilities		0		(292	)		0			(292	)		0		(458	)		0			(458	)
	Total		$	0	$	1,021		($	1,037	)	($	16	)	$	3,634	$	871		($	981	)	$	3,524

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Weighted Average Input Assumptions	'
	The fair value of stock options granted during the three months ended March 31, 2013 was determined using the Black-Scholes-Merton valuation model and reflects the below input assumptions. No stock options were granted during the three months ended March 31, 2014.
		Three Months Ended March 31, 2013
	Weighed-average exercise price	$	12.72
	Expected term ( in years)		4.75
	Expected volatility		55.9	%
	Expected dividend yield		0	%
	Risk-free interest rate		0.8	%
Stock-Based Compensation Expense	'
	Stock-based compensation expense recognized during the three months ended March 31, 2014 and 2013 is included in our consolidated statements of operations as follows:
		Three Months Ended March 31,
	(In thousands)	2014			2013
	Cost of revenue:
	Professional services	$	606		$	577
	Maintenance		330			381
	Transaction processing and other		402			424
	Total cost of revenue		1,338			1,382
	Selling, general and administrative expenses		6,178			4,726
	Research and development		2,554			1,896
	Total stock-based compensation expense	$	10,070		$	8,004
Stock-Based Awards Granted	'
	We granted stock-based awards as follows:
		Three Months Ended March 31, 2014
	(In thousands, except per share amounts)	Shares			Weighted-Average
					Grant Date
					Fair Value
	Service-based restricted stock units		1,302		$	18.47
	Performance-based restricted stock units with a service condition		467		$	18.51
	Market-based restricted stock units with a service condition		221		$	14.36
			1,990		$	18.03

Earnings_Loss_Per_Share_Tables

Earnings (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Calculations of Earnings (Loss) Per Share	'
	The calculations of earnings (loss) per share are as follows:
		Three Months Ended March 31,
	(In thousands, except per share amounts)	2014			2013
	Basic Loss per Common Share:
	Net loss	($	20,742	)	($	11,592	)
	Net loss available to common stockholders	($	20,742	)	($	11,592	)
	Weighted-average common shares outstanding		179,033			173,710
	Basic Loss per Common Share	($	0.12	)	($	0.07	)
	Diluted Loss per Common Share:
	Net loss	($	20,742	)	($	11,592	)
	Net loss available to common stockholders	($	20,742	)	($	11,592	)
	Weighted-average common shares outstanding		179,033			173,710
	Dilutive effect of stock options, restricted stock unit awards and warrants		0			0
	Weighted-average common shares outstanding assuming dilution		179,033			173,710
	Diluted Loss per Common Share	($	0.12	)	($	0.07	)
Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted (Loss) Earnings Per Share	'
	The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted (loss) earnings per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive:
		Three Months Ended March 31,
	(In thousands)	2014			2013
	Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation		21,721			3,668

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets	'
	Goodwill and intangible assets consist of the following:
		March 31, 2014							December 31, 2013
	(In thousands)	Gross		Accumulated			Intangible		Gross		Accumulated			Intangible
		Carrying		Amortization			Assets,  Net		Carrying		Amortization			Assets,  Net
		Amount							Amount
	Intangibles subject to amortization
	Proprietary technology	$	445,960	($	240,548	)	$	205,412	$	445,960	($	231,634	)	$	214,326
	Customer contracts and relationships		544,073		(359,432	)		184,641		542,205		(352,560	)		189,645
	Total	$	990,033	($	599,980	)	$	390,053	$	988,165	($	584,194	)	$	403,971
	Intangibles not subject to amortization
	Registered trademarks						$	52,000						$	52,000
	Goodwill							1,190,603							1,189,585
	Total						$	1,242,603						$	1,241,585
Changes in Carrying Amount of Goodwill	'
	Changes in the carrying amounts of goodwill by reportable segment for the three months ended March 31, 2014 were as follows:
	(In thousands)	Clinical and		Population			Managed		Total
		Financial  Solutions		Health			Services
	Balance as of December 31, 2013	$	625,769	$	425,216		$	138,600	$	1,189,585
	Additions arising from business acquisitions:
	dbMotion		0		1,018			0		1,018
	Total additions to goodwill		0		1,018			0		1,018
	Impairment of goodwill		0		0			0		0
	Balance as of March 31, 2014	$	625,769	$	426,234		$	138,600	$	1,190,603

Debt_Tables

Debt (Tables)	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Debt Outstanding Excluding Capital Leases	'
	Debt outstanding, excluding capital leases, consisted of the following:
			March 31, 2014						December 31, 2013
	(In thousands)		Principal		Unamortized		Net		Principal		Unamortized		Net
			Balance		Discount		Carrying		Balance		Discount		Carrying
							Amount						Amount
	1.25% Cash Convertible Senior Notes		$	345,000	$	75,014	$	269,986	$	345,000	$	77,529	$	267,471
	Senior Secured Credit Facilities (long-term portion)			261,875		2,106		259,769		280,000		2,338		277,662
	Senior Secured Credit Facilities (current portion)			19,688		963		18,725		16,875		982		15,893
	Total debt		$	626,563	$	78,083	$	548,480	$	641,875	$	80,849	$	561,026
Interest Expense	'
	Interest expense consisted of the following:
			Three Months Ended March 31,
	(In thousands)		2014		2013
	Interest expense		$	3,957	$	3,337
	Amortization of discounts			2,766		0
	Amortization of debt issuance costs			510		1,300
	Total interest expense		$	7,233	$	4,637
Interest Expense Related to Notes	'
	Interest expense related to the 1.25% Notes was comprised of the following:
			Three Months Ended March 31,
	(In thousands)		2014		2013
	Coupon interest at 1.25%		$	1,078	$	0
	Amortization of original issuance discount			2,515		0
	Amortization of debt issuance costs			295		0
	Total interest expense related to the 1.25% Notes		$	3,888	$	0
Summary of Future Payment Obligations under Notes and Senior Secured Credit Facilities	'
	The following table summarizes our future payment obligations under the 1.25% Notes and the senior secured credit facility as of March 31, 2014:
	(Dollar amounts in thousands)		Total		Remainder of		2015		2016		2017		2018		Thereafter
					2014
	1.25% Cash Convertible Senior Notes (1)		$	345,000	$	0	$	0	$	0	$	0	$	0	$	345,000
	Senior Secured Term Loan			216,563		14,063		28,125		39,375		50,625		84,375		0
	Senior Secured Revolving Facility			65,000		0		0		0		0		65,000		0
			$	626,563	$	14,063	$	28,125	$	39,375	$	50,625	$	149,375	$	345,000
	-1	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

Income_Taxes_Tables

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Effective Tax Rates	'
	The effective tax rates were as follows:
		Three Months Ended March 31,
	(Dollar amounts in thousands)	2014			2013
	Loss before income taxes	($	19,176	)	($	24,789	)
	Income tax (provision) benefit	($	1,566	)	$	13,197
	Effective tax rate		(8.2	%)		53.2	%

Derivative_Financial_Instrumen1

Derivative Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2014
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'
Activity Related to Interest Rate Swap Agreement	'
	We recognized the following activity related to our interest rate swap agreement:
		Three Months Ended March 31,
	(In thousands)	2014			2013
	Effective Portion
	Current period increase in fair value recognized in OCI	$	166		$	353
	Tax effect		(66	)		(136	)
	Net	$	100		$	217
	Loss reclassified from OCI to interest expense	$	199		$	359
	Amount excluded from Effectiveness Assessment and Ineffective Portion Gain (loss) recognized in other income (expense)	$	0		$	0

Business_Segments_Tables

Business Segments (Tables)	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Revenues and Income from Operations Related to Segment Within Reconciliation to Consolidated Amounts	'
		Three Months Ended March 31,
	(In thousands)	2014			2013
	Revenue:
	Clinical and Financial Solutions	$	205,386		$	217,943
	Population Health		70,028			60,529
	Managed Services		61,921			59,732
	Unallocated Amounts		2,950			8,862
	Total revenue	$	340,285		$	347,066
	Gross Profit:
	Clinical and Financial Solutions	$	99,032		$	101,590
	Population Health		48,694			37,840
	Managed Services		5,728			7,555
	Unallocated Amounts		(15,268	)		(12,557	)
	Total gross profit	$	138,186		$	134,428
	Income (Loss) from operations:
	Clinical and Financial Solutions	$	43,215		$	42,577
	Population Health		24,279			21,115
	Managed Services		5,728			7,555
	Unallocated Amounts		(85,133	)		(99,530	)
	Total loss from operations	($	11,911	)	($	28,283	)

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	Mar. 31, 2014
In Millions, unless otherwise specified
Accounting Policies [Abstract]	'
Unrecognized tax benefit presented as a reduction to deferred tax asset	$4

Business_Combinations_Addition

Business Combinations - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended
In Millions, unless otherwise specified	Mar. 04, 2013	Mar. 31, 2014	Mar. 31, 2013
dbMotion [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Date of Acquisition	'	4-Mar-13	'
Increase in fair value of the consideration transferred	'	1	'
dbMotion [Member] | Purchase Price Allocation Adjustments [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Increase in goodwill	'	1	'
dbMotion [Member] | Selling, General and Administrative Expenses [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Acquisition-related costs	'	1.8	1.4
Additional employee compensation expected to be incurred in future, description	'	'Additional employee compensation of approximately $1.4 million related to the dbMotion acquisition is expected to be incurred during the remainder of 2014.	'
dbMotion [Member] | Selling, General and Administrative Expenses [Member] | Acquisition-related Costs [Member] | Employee Compensation Costs [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Acquisition-related costs	'	1.8	0.5
dbMotion [Member] | Selling, General and Administrative Expenses [Member] | Acquisition-related Costs [Member] | Seller Transaction Costs [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Acquisition-related costs	'	'	0.5
dbMotion [Member] | Selling, General and Administrative Expenses [Member] | Scenario, Forecast [Member] | Acquisition-related Costs [Member] | Employee Compensation Costs [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Acquisition-related costs	'	1.4	'
dbMotion [Member] | Cost of revenue [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Amortization of software development costs and acquisition-related assets	'	'	1.2
dbMotion [Member] | System sales [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Amortization of software development costs and acquisition-related assets	'	'	0.4
dbMotion [Member] | Professional services [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Amortization of software development costs and acquisition-related assets	'	'	0.6
dbMotion [Member] | Maintenance [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Amortization of software development costs and acquisition-related assets	'	'	0.2
Jardogs [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Date of Acquisition	'	4-Mar-13	'
Acquisition-related costs	'	'	0.7
Aggregate consideration with a fair value	$24	'	'

Fair_Value_of_Consideration_Tr

Fair Value of Consideration Transferred for Acquisition (Detail) (dbMotion [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
dbMotion [Member]	'
Business Acquisition [Line Items]	'
Cash	$140,079
Allscripts common stock, 3,823,453 shares, par value $0.01 per share, fair value at closing $12.57 per share	48,061
Deferred cash consideration payable on the 18-month anniversary of the closing	23,023
Subordinated promissory note maturing 18 months following the closing	6,648
Fair value of Allscripts' previous interest in dbMotion	8,367
Total fair value of consideration transferred	$226,178

Fair_Value_of_Consideration_Tr1

Fair Value of Consideration Transferred for Acquisition (Parenthetical) (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014
			dbMotion [Member]
Business Acquisition [Line Items]	'	'	'
Common stock, shares	264,093,000	263,474,000	3,823,453
Common stock, par value	$0.01	$0.01	$0.01
Common stock, fair value	'	'	$12.57
Deferred cash consideration payable anniversary	'	'	'18 months
Subordinated promissory note maturing period	'	'	'18 months

Assets_Acquired_and_Liabilitie

Assets Acquired and Liabilities Assumed (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Business Acquisition [Line Items]	'	'
Goodwill	$1,190,603	$1,189,585
dbMotion [Member]	'	'
Business Acquisition [Line Items]	'	'
Acquired cash and cash equivalents, and restricted cash	14,188	'
Accounts receivable, net	3,226	'
Prepaid expenses and other current assets	574	'
Fixed assets and other long-term assets	1,449	'
Goodwill	137,649	'
Intangible assets	85,450	'
Accounts payable and accrued liabilities	-10,560	'
Deferred taxes, net	-36	'
Deferred revenue	-5,100	'
Other liabilities	-662	'
Net assets acquired	$226,178	'

Proforma_Results_Detail

Proforma Results (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2013
dbMotion [Member]	'
Business Acquisition [Line Items]	'
Revenue	$174
Net loss	-2,847
Combined Entity [Member]	'
Business Acquisition [Line Items]	'
Revenue	348,260
Net loss	($23,014)
Net loss per share, basic and diluted	($0.13)

Summary_of_Financial_Assets_an

Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total	($16)	$3,524
Interest rate swap [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Other liabilities	-292	-458
Money market funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	0	3,634
Marketable securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Long-term marketable securities	1,313	1,329
1.25% Call Option [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Other assets	134,600	104,656
Cash conversion option [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Other liabilities	-135,637	-105,637
Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total	0	3,634
Level 1 [Member] | Interest rate swap [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Other liabilities	0	0
Level 1 [Member] | Money market funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	0	3,634
Level 1 [Member] | Marketable securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Long-term marketable securities	0	0
Level 1 [Member] | 1.25% Call Option [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Other assets	0	0
Level 1 [Member] | Cash conversion option [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Other liabilities	0	0
Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total	1,021	871
Level 2 [Member] | Interest rate swap [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Other liabilities	-292	-458
Level 2 [Member] | Money market funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	0	0
Level 2 [Member] | Marketable securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Long-term marketable securities	1,313	1,329
Level 2 [Member] | 1.25% Call Option [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Other assets	0	0
Level 2 [Member] | Cash conversion option [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Other liabilities	0	0
Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total	-1,037	-981
Level 3 [Member] | Interest rate swap [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Other liabilities	0	0
Level 3 [Member] | Money market funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	0	0
Level 3 [Member] | Marketable securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Long-term marketable securities	0	0
Level 3 [Member] | 1.25% Call Option [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Other assets	134,600	104,656
Level 3 [Member] | Cash conversion option [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Other liabilities	($135,637)	($105,637)

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	Mar. 31, 2014
In Millions, unless otherwise specified
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'
Total consideration for non marketable equity securities	$6
Value of equity investment	4.1
Value of commercial agreement	$1.90
1.25% Cash Convertible Senior Notes [Member]	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'
Interest rate	1.25%

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	1 Months Ended		3 Months Ended			12 Months Ended
In Millions, except Share data, unless otherwise specified	Apr. 30, 2012	Apr. 30, 2011	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2013
Capital Unit [Line Items]	'	'	'	'	'	'
Stock options granted	'	'	0	'	'	'
Capitalized stock-based compensation costs	'	'	$0	$0	'	'
Share issued, exercise of options and release of stock awards	'	'	600,000	'	'	2,600,000
Stock repurchase program, amount authorized	'	200	'	'	'	'
Stock repurchase program, expiring date	'	9-May-14	'	'	'	'
Stock repurchase program, authorized repurchase period (in years)	'	'3 years	'	'	'	'
Stock repurchase program, additional authorized amount	200	'	'	'	'	'
Stock repurchase program, total authorized amount	400	'	'	'	'	'
Stock repurchase program, remaining amount authorized	'	'	123	'	'	'
Common stock repurchased, shares	'	'	0	'	'	0
Shares settled for tax withholding	'	'	174,000	'	125,000	'
1.25% Warrants [Member] | Commercial Partner [Member]	'	'	'	'	'	'
Capital Unit [Line Items]	'	'	'	'	'	'
Number of warrants issued	'	'	1,500,000	'	'	'
Initial exercise price of warrant per share	'	'	12.94	'	'	'
Number of installments	'	'	4	'	'	'
Number of warrants vested during period	'	'	375,000	'	'	'
Warrant expiration period	'	'	'2020-06	'	'	'
Fair value recognized as reduction to transaction processing and other revenues	'	'	$0.60	'	'	'

Weighted_Average_Grant_Date_Fa

Weighted Average Grant Date Fair Value Information and Related Valuation Assumptions (Detail) (USD $)	3 Months Ended
	Mar. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Weighed-average exercise price	$12.72
Expected term ( in years)	'4 years 9 months
Expected volatility	55.90%
Expected dividend yield	0.00%
Risk-free interest rate	0.80%

StockBased_Compensation_Expens

Stock-Based Compensation Expense (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock based compensation expense	$10,070	$8,004
Cost of revenue [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock based compensation expense	1,338	1,382
Cost of revenue [Member] | Professional Services [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock based compensation expense	606	577
Cost of revenue [Member] | Maintenance [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock based compensation expense	330	381
Cost of revenue [Member] | Transaction processing and other [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock based compensation expense	402	424
Selling, General and Administrative Expenses [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock based compensation expense	6,178	4,726
Research and development [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock based compensation expense	$2,554	$1,896

StockBased_Awards_Granted_Deta

Stock-Based Awards Granted (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Shares, granted	1,990
Weighted-Average Grant Date Fair Value, granted	$18.03
Service-Based Restricted Stock Units [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Shares, granted	1,302
Weighted-Average Grant Date Fair Value, granted	$18.47
Performance-Based Restricted Stock Units with a Service Condition [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Shares, granted	467
Weighted-Average Grant Date Fair Value, granted	$18.51
Market Based Restricted Stock Units with a Service Condition [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Shares, granted	221
Weighted-Average Grant Date Fair Value, granted	$14.36

Calculations_of_Earnings_Loss_

Calculations of Earnings (Loss) Per Share (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Earnings Per Share [Abstract]	'	'
Net loss	($20,742)	($11,592)
Net loss available to common stockholders	-20,742	-11,592
Weighted-average common shares outstanding	179,033	173,710
Basic Loss per Common Share	($0.12)	($0.07)
Net loss	-20,742	-11,592
Net loss available to common stockholders	($20,742)	($11,592)
Weighted-average common shares outstanding	179,033	173,710
Dilutive effect of stock options, restricted stock unit awards and warrants	0	0
Weighted-average common shares outstanding assuming dilution	179,033	173,710
Diluted Loss per Common Share	($0.12)	($0.07)

AntiDilutive_Stock_Options_Res

Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted (Loss) Earnings Per Share (Detail)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Earnings Per Share [Abstract]	'	'
Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation	21,721	3,668

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule Of Goodwill And Intangible Assets [Line Items]	'	'
Gross Carrying Amount	$990,033	$988,165
Accumulated Amortization	-599,980	-584,194
Intangible Assets, Net	390,053	403,971
Registered trademarks	52,000	52,000
Goodwill	1,190,603	1,189,585
Total	1,242,603	1,241,585
Proprietary Technology [Member]	'	'
Schedule Of Goodwill And Intangible Assets [Line Items]	'	'
Gross Carrying Amount	445,960	445,960
Accumulated Amortization	-240,548	-231,634
Intangible Assets, Net	205,412	214,326
Customer Contracts and Relationships [Member]	'	'
Schedule Of Goodwill And Intangible Assets [Line Items]	'	'
Gross Carrying Amount	544,073	542,205
Accumulated Amortization	-359,432	-352,560
Intangible Assets, Net	$184,641	$189,645

Changes_in_Carrying_Amount_of_

Changes in Carrying Amount of Goodwill (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Schedule Of Goodwill And Intangible Assets [Line Items]	'	'
Goodwill	$1,189,585	'
Additions arising from business acquisitions	1,018	'
Impairment of goodwill	0	'
Goodwill, net	1,190,603	1,189,585
dbMotion [Member]	'	'
Schedule Of Goodwill And Intangible Assets [Line Items]	'	'
Additions arising from business acquisitions	1,018	'
Goodwill, net	137,649	'
Clinical and Financial Solutions [Member]	'	'
Schedule Of Goodwill And Intangible Assets [Line Items]	'	'
Goodwill	625,769	'
Additions arising from business acquisitions	0	'
Impairment of goodwill	0	'
Goodwill, net	625,769	'
Clinical and Financial Solutions [Member] | dbMotion [Member]	'	'
Schedule Of Goodwill And Intangible Assets [Line Items]	'	'
Additions arising from business acquisitions	0	'
Population Health [Member]	'	'
Schedule Of Goodwill And Intangible Assets [Line Items]	'	'
Goodwill	425,216	'
Additions arising from business acquisitions	1,018	'
Impairment of goodwill	0	'
Goodwill, net	426,234	'
Population Health [Member] | dbMotion [Member]	'	'
Schedule Of Goodwill And Intangible Assets [Line Items]	'	'
Additions arising from business acquisitions	1,018	'
Managed Services [Member]	'	'
Schedule Of Goodwill And Intangible Assets [Line Items]	'	'
Goodwill	138,600	'
Additions arising from business acquisitions	0	'
Impairment of goodwill	0	'
Goodwill, net	138,600	'
Managed Services [Member] | dbMotion [Member]	'	'
Schedule Of Goodwill And Intangible Assets [Line Items]	'	'
Additions arising from business acquisitions	$0	'

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets - Additional Information (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'	'
Accumulated impairment losses associated with goodwill	$0	$0

Debt_Outstanding_Excluding_Cap

Debt Outstanding Excluding Capital Lease Obligations (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'
Principal Balance	$626,563	$641,875
Unamortized Discount	78,083	80,849
Net Carrying Amount	548,480	561,026
1.25% Cash Convertible Senior Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Principal Balance	345,000	345,000
Unamortized Discount	75,014	77,529
Net Carrying Amount	269,986	267,471
Senior Secured Credit Facilities (long-term portion) [Member]	'	'
Debt Instrument [Line Items]	'	'
Principal Balance	261,875	280,000
Unamortized Discount	2,106	2,338
Net Carrying Amount	259,769	277,662
Senior Secured Credit Facilities (current portion) [Member]	'	'
Debt Instrument [Line Items]	'	'
Principal Balance	19,688	16,875
Unamortized Discount	963	982
Net Carrying Amount	$18,725	$15,893

Interest_Expense_Detail

Interest Expense (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Debt Disclosure [Abstract]	'	'
Interest expense	$3,957	$3,337
Amortization of discounts	2,766	0
Amortization of debt issuance costs	510	1,300
Total interest expense	$7,233	$4,637

Interest_Expense_Related_to_No

Interest Expense Related to Notes (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Debt Instrument [Line Items]	'	'
Coupon interest at 1.25%	$3,957	$3,337
Amortization of original issuance discount	2,766	0
Amortization of debt issuance costs	510	1,300
Total interest expense	7,233	4,637
1.25% Cash Convertible Senior Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Coupon interest at 1.25%	1,078	0
Amortization of original issuance discount	2,515	0
Amortization of debt issuance costs	295	0
Total interest expense	$3,888	$0

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 31, 2014
Debt Instrument [Line Items]	'
Closing price of common stock	$18.03
Conversion price of common stock	$17.19
Letters of credit outstanding	$1.10
Credit facility interest rate	2.75%
Unamortized deferred debt issuance costs	11
LIBOR [Member]	'
Debt Instrument [Line Items]	'
Total interest rate	2.90%
Senior Secured Term Loan [Member]	'
Debt Instrument [Line Items]	'
Borrowings outstanding in term loan	216.6
Senior Secured Revolving Facility [Member]	'
Debt Instrument [Line Items]	'
Credit facility, amount borrowed	65
Credit facility, amount available	$358.90
1.25% Cash Convertible Senior Notes [Member]	'
Debt Instrument [Line Items]	'
Interest rate	1.25%

Summary_of_Future_Payment_Obli

Summary of Future Payment Obligations under Notes and Senior Secured Credit Facilities (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'
Total	$626,563	$641,875
Remainder of 2014	14,063	'
2015	28,125	'
2016	39,375	'
2017	50,625	'
2018	149,375	'
Thereafter	345,000	'
1.25% Cash Convertible Senior Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Total	345,000	345,000
Remainder of 2014	0	'
2015	0	'
2016	0	'
2017	0	'
2018	0	'
Thereafter	345,000	'
Senior Secured Term Loan [Member]	'	'
Debt Instrument [Line Items]	'	'
Total	216,563	'
Remainder of 2014	14,063	'
2015	28,125	'
2016	39,375	'
2017	50,625	'
2018	84,375	'
Thereafter	0	'
Senior Secured Revolving Facility [Member]	'	'
Debt Instrument [Line Items]	'	'
Total	65,000	'
Remainder of 2014	0	'
2015	0	'
2016	0	'
2017	0	'
2018	65,000	'
Thereafter	$0	'

Summary_of_Future_Payment_Obli1

Summary of Future Payment Obligations under Notes and Senior Secured Credit Facilities (Parenthetical) (Detail)	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
1.25% notes maturity period	1-Jul-20

Effective_Tax_Rates_Detail

Effective Tax Rates (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Income Tax Disclosure [Abstract]	'	'
Loss before income taxes	($19,176)	($24,789)
Income tax (provision) benefit	($1,566)	$13,197
Effective tax rate	-8.20%	53.20%

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'	'
Valuation Allowance	$10	'
Cumulative operating income loss period considered	'3 years	'
Unrecognized income tax benefits	$18.20	$18.30

Derivative_Financial_Instrumen2

Derivative Financial Instruments - Additional Information (Detail) (USD $)

0 Months Ended

3 Months Ended

3 Months Ended

Oct. 29, 2010

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Jun. 18, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Oct. 29, 2010

1.25% Notes Embedded Cash Conversion Options [Member]

1.25% Notes Embedded Cash Conversion Options [Member]

1.25% Notes Embedded Cash Conversion Options [Member]

1.25% Call Option [Member]

1.25% Call Option [Member]

1.25% Call Option [Member]

1.25% Call Option [Member]

Interest rate swap [Member]

Interest rate swap [Member]

Interest rate swap [Member]

Short [Member]

Short [Member]

Level 3 [Member]

Level 3 [Member]

1.25% Notes Embedded Cash Conversion Options [Member]

Fair Value Measurements [Member]

Fair Value Measurements [Member]

Derivative [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of option

'

'

'

'

'

'

'

'

$134,600,000

$104,700,000

'

'

'

Gain (Loss) on call options

'

'

'

'

'

'

30,000,000

29,900,000

'

'

'

'

'

Fair value liability of embedded cash conversion option

'

'

'

135,600,000

105,600,000

82,800,000

'

'

'

'

'

'

'

Interest rate swap agreement effective date

29-Oct-10

'

'

'

'

'

'

'

'

'

'

'

'

Notional amount of interest rate swap agreement

'

'

'

'

'

'

'

'

'

'

100,000,000

'

300,000,000

Interest rate swap agreement termination date

31-Oct-14

'

'

'

'

'

'

'

'

'

'

'

'

Effective fixed interest rate for swap agreement

'

0.90%

'

'

'

'

'

'

'

'

'

'

'

Fair value of interest rate swap agreement

'

'

'

'

'

'

'

'

'

'

300,000

500,000

'

Derivative losses included in OCI to be reclassified into earnings within next 12 months

'

300,000

'

'

'

'

'

'

'

'

'

'

'

Variable effective interest rate for swap agreement

'

2.90%

'

'

'

'

'

'

'

'

'

'

'

Gains (losses) reclassified from OCI into earnings due to forecasted transactions that failed to occur

'

$0

$0

'

'

'

'

'

'

'

'

'

'

Activity_Related_to_Interest_R

Activity Related to Interest Rate Swap Agreement (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'	'
Current period increase in fair value recognized in OCI	$166	$353
Tax effect	-66	-136
Unrealized gain on interest rate swap, net of tax	100	217
Loss reclassified from OCI to interest expense	199	359
Amount excluded from Effectiveness Assessment and Ineffective Portion Gain (loss) recognized in other income (expense)	$0	$0

Contingencies_Additional_Infor

Contingencies - Additional Information (Detail) (USD $)	3 Months Ended		0 Months Ended
	Mar. 31, 2014	1-May-12	Feb. 26, 2013
			Minimum [Member]
			Cardinal Health 200, LLC [Member]
Loss Contingencies [Line Items]	'	'	'
Contingency allegations	'Counterclaims against Pegasus for breach of two license agreements, breach of warranty, breach of a settlement and arbitration agreement, and three counts of negligent misrepresentation	'	'
Damages for alleged breaches of Contract	'	'	$3,978,000
Damages sought per alleged violation of the TCPA	'	$500	'

Business_Segments_Additional_I

Business Segments - Additional Information (Detail)	1 Months Ended		3 Months Ended
	Mar. 31, 2014	Nov. 30, 2013	Mar. 31, 2014
	Segment	Segment	Segment
Segment Reporting [Abstract]	'	'	'
Number of reportable segments	3	5	'
Number of operating segments	'	'	9

Revenues_and_Income_from_Opera

Revenues and Income from Operations Related to Segment Within Reconciliation to Consolidated Amounts (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Segment Reporting Information [Line Items]	'	'
Revenue	$340,285	$347,066
Gross Profit	138,186	134,428
Income (Loss) from operations	-11,911	-28,283
Unallocated Amounts [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue	2,950	8,862
Gross Profit	-15,268	-12,557
Income (Loss) from operations	-85,133	-99,530
Clinical and Financial Solutions [Member] | Operating Segments [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue	205,386	217,943
Gross Profit	99,032	101,590
Income (Loss) from operations	43,215	42,577
Population Health [Member] | Operating Segments [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue	70,028	60,529
Gross Profit	48,694	37,840
Income (Loss) from operations	24,279	21,115
Managed Services [Member] | Operating Segments [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue	61,921	59,732
Gross Profit	5,728	7,555
Income (Loss) from operations	$5,728	$7,555

North_American_Site_Consolidat1

North American Site Consolidation Plan - Additional Information (Detail) (North American Site Consolidation Plan [Member], USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Feb. 18, 2013
				Warehouse
				Office
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Number of offices closed under the Site Consolidation Plan	'	'	'	12
Number of Warehouse closed under the Site Consolidation Plan	'	'	'	1
Severance costs incurred	($2)	$11	'	'
Payments of severance costs	1	'	'	'
Accrued severance costs	1.2	11.2	4.2	'
Scenario, Forecast [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Future lease exit cost	$1	'	'	'